Remdesivir for the Treatment of Human Coronavirus OC43 Encephalitis
Human coronavirus OC43 (HCoV-OC43) is predominantly associated with mild respiratory infections. HCoV-OC43 also has neuroinvasive properties, and severe encephalitis has been described in immunocompromised patients, with fatal outcomes due to the lack of specific antiviral treatment. We report a case of severe febrile encephalitis attributed to HCoV-OC43 that progressively worsened over 3 months in a 65-year-old immunocompromised man. Clinical symptoms improved remarkably after treatment with remdesivir, with an increase of the Glasgow Coma Score from 8 to 14 within 7 days.
Authors
- Marine Dupont (ORCID: https://orcid.org/0000-0001-8703-7145)
- Jacques Fourgeaud (ORCID: https://orcid.org/0000-0003-3631-184X)
- Pascal Turlure
- Nolwenn Marie Dheilly (ORCID: https://orcid.org/0000-0002-3675-5013)
- Nicolas Veyrenche (ORCID: https://orcid.org/0000-0001-5948-5039)
- Pierre Frange (ORCID: https://orcid.org/0000-0002-4920-8369)
- Sophie Alain (ORCID: https://orcid.org/0000-0002-9787-1421)
- Clémence Busquet
- Marianne Leruez‐Ville (ORCID: https://orcid.org/0000-0001-7513-7894)
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Institut Pasteur (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Université de Limoges (FR)
Publication Details
- Journal
- Journal of Medical Virology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/jmv.70314
- Citations
- 2
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 2.78